Circulating Tumour DNA and Its Prognostic Role in Management of Muscle Invasive Bladder Cancer: A Narrative Review of the Literature DOI Creative Commons
Konstantinos Kapriniotis, Lazaros Tzelves, Lazaros Lazarou

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(4), P. 921 - 921

Published: April 21, 2024

Current management of non-metastatic muscle invasive bladder cancer (MIBC) includes radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC), offers a 5-year survival rate approximately 50% is associated with significant toxicities. A growing body evidence supports the role liquid biopsies including circulating tumour DNA (ctDNA) as prognostic predictive marker that could stratify patients according to individualised risk progression/recurrence. Detectable ctDNA levels prior have been shown be correlated higher recurrence worse overall prognosis after cystectomy. In addition, status NAC/neoadjuvant immunotherapy pathological response these treatments, persistently detectable being residual at Finally, post-cystectomy disease relapse disease-free (DFS) (OS) might identify population benefit from adjuvant immunotherapy.

Language: Английский

Bladder cancer DOI
Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou

et al.

Nature Reviews Disease Primers, Journal Year: 2023, Volume and Issue: 9(1)

Published: Oct. 26, 2023

Language: Английский

Citations

170
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice DOI
Lisa M.C. van Hoogstraten, Alina Vrieling, Antoine G. van der Heijden

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(5), P. 287 - 304

Published: March 13, 2023

Language: Английский

Citations

157
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis DOI Creative Commons
Shitao Jiang, Y. Liu, Han Zheng

et al.

International Journal of Surgery, Journal Year: 2023, Volume and Issue: unknown

Published: May 22, 2023

Research has shown that neoadjuvant immunotherapy may provide more significant clinical benefits to cancer patients undergoing surgery than adjuvant therapy. This study examines the development of research using bibliometric analysis. As February 12, 2023, articles on in Web Science Core Collection (WoSCC) were collected. Co-authorship and keyword co-occurrence analyses visualizations performed VOSviewer, while CiteSpace was used identify bursting keywords references. The analyzed a total 1,222 publications. top contributors this field United States (US), China, Italy, journal with most publications Frontiers Oncology. Francesco Montorsi had highest H-index. common “immunotherapy” “neoadjuvant therapy.” conducted analysis over 20 years research, identifying countries, institutions, authors, journals, involved field. findings comprehensive overview research.

Language: Английский

Citations

83
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma DOI Creative Commons
Iver Nordentoft, Sia V. Lindskrog, Karin Birkenkamp‐Demtröder

et al.

European Urology, Journal Year: 2024, Volume and Issue: 86(4), P. 301 - 311

Published: May 29, 2024

Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability detecting ctDNA in settings low burden is limited by number mutations analyzed and plasma volume available. We a whole-genome sequencing (WGS) approach patients with urothelial carcinoma.

Language: Английский

Citations

17
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review DOI
Emanuele Crupi, Tiago Costa de Pádua, Laura Marandino

et al.

European Urology Oncology, Journal Year: 2023, Volume and Issue: 7(1), P. 44 - 52

Published: June 16, 2023

Language: Английский

Citations

26
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up DOI Creative Commons
Sia V. Lindskrog, Karin Birkenkamp‐Demtröder, Iver Nordentoft

et al.

Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 29(23), P. 4797 - 4807

Published: Oct. 2, 2023

Abstract Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full follow-up results (median follow-up: 68 months) from a previously described cohort neoadjuvant chemotherapy (NAC)-treated who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed evaluation 153 samples collected before after radical cystectomy (RC) separate 102 NAC-naïve 72 months). Total RNA sequencing tumors was to biological characteristics shedding tumors. Results: Assessment RC identified relapse sensitivity 94% specificity 98% using the expanded data for NAC-treated patients. dynamics during NAC independently associated patient outcomes when adjusted pathologic downstaging (HR = 4.7; P 0.029). For patients, prognostic predictor 3.4; 0.0005) 17.8; 0.0002). No statistically significant difference recurrence-free survival without detectable at diagnosis observed between cohorts. Baseline positivity Basal/Squamous (Ba/Sq) subtype enrichment epithelial-to-mesenchymal transition cell cycle–associated gene sets. Conclusions: is more than 5 years outperforms predicting efficacy. Patients may benefit significantly less NAC, but additional studies are needed.

Language: Английский

Citations

26
The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples DOI Creative Commons
Hongwei Peng, Ming Pan, Zongning Zhou

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: May 9, 2024

Cell-free DNA (cfDNA), a burgeoning class of molecular biomarkers, has been extensively studied across variety biomedical fields. As key component liquid biopsy, cfDNA testing is gaining prominence in disease detection and management due to the convenience sample collection abundant wealth genetic information it provides. However, broader clinical application currently impeded by lack standardization preanalytical procedures for analysis. A number fundamental challenges, including selection appropriate procedures, prevention short fragment loss, validation various measurement methods, remain unaddressed. These existing hurdles lead difficulties comparing results ensuring repeatability, thereby undermining reliability analysis settings. This review discusses crucial factors that influence outcomes, collection, transportation, temporary storage, processing, extraction, quality control, long-term storage. The provides clarification on achievable consensus offers an current issues with goal standardizing

Language: Английский

Citations

8
Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis DOI Creative Commons

Xindong Gao,

Wenqiang Qi,

Junxian Li

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 1, 2025

At present, there is no effective prognostic indicator for muscle invasive bladder cancer (MIBC). A liquid biopsy method, plasma circulating tumor DNA (ctDNA) detection, was evaluated use in predicting the prognosis of different cancers. This study aims to assess value ctDNA state muscle-invasive patients. We comprehensively searched three public databases (PubMed, EMBASE, and Cochrane Library) December 2023 according Preferred Reporting Items Systematic Review Meta-analysis (PRISMA) statement. Studies investigating outcome indicators patients with MIBC were included our analysis. The hazard ratios (HRs) 95% confidence intervals (CIs) extracted evaluate association between MIBC. Eleven studies 1,170 diagnosed cancer, comprising a total four retrospective cohort eight prospective studies, meta-analysis, one which had two cohorts. analysis revealed that positive associated poor overall survival (OS), progression-free (PFS), recurrence-free (RFS) (HR = 4.51, CI: 2.64–7.69, P < 0.001; HR 4.50, 2.77–7.30, 6.56, 4.18–10.30, 0.001), significant effects both pre- post-treatment. In addition, longitudinal proved be monitoring receiving treatments 0.24, 0.14–0.41, 0.001). OS, PFS, RFS Meanwhile, clearance improved These findings suggest predictive MIBC, can used monitor recurrence guide treatment. Thus, level detection shows potential treatment

Language: Английский

Citations

1
The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition DOI Creative Commons
Jeroen van Dorp, Michiel S. van der Heijden

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 31, 2023

Treatment with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the default treatment for muscle-invasive bladder cancer (BC). However, encouraging results of immune checkpoint inhibitiors (ICI) directed against PD-1/PD-L1 and CTLA-4 in recent years, landscape BC rapidly changing. In addition, it becoming clear that effect ICI highly dependent on interaction between tumor cells micro-environment (TIME). Different are involved an anti-tumor response BC. Cytotoxic CD8 + T-cells main effector cells, aided other including T-cells, B-cells pro-inflammatory macrophages. As part ongoing response, lymphocytes aggregate clusters called tertiary lymphoid structures (TLS). Tumor mutational burden (TMB) infiltration into both important factors establishing response. contrast, transforming growth factor beta (TGF-β) signaling cancer-associated fibroblasts (CAFs) prevents potentially has immunosuppressive effect. conclusion, seems to be reliant a combination tumor-intrinsic TIME-related parameters. More research needed fully understand underlying biological mechanisms further improve patient care.

Language: Английский

Citations

18
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors DOI Creative Commons

Alberto Gil-Jimenez,

Nick van Dijk, Joris L. Vos

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: March 21, 2024

Abstract Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between TME, usually characterized by immune cell density, and response to ICI is unclear. Here, we quantify TME densities spatial relationships (SRs) of 24 baseline UC samples, obtained before pre-operative combination treatment, using multiplex immunofluorescence. We describe SRs approximating first nearest-neighbor distance distribution with a Weibull evaluate association metrics ipilimumab+nivolumab response. density does not discriminate groups. SR CD8 + T cells or macrophages their closest positively associate close B are characteristic non-response. validate our associations cohort head neck tumors. Our data confirm that SRs, contrast metrics, strong biomarkers ICIs.

Language: Английский

Citations

6